Immunohistochemistry in dermatopathology: A review of the most commonly used antibodies (part ii);Inmunohistoquímica en dermatopatología: revisión de los anticuerpos utilizados con mayor frecuencia (parte ii)

Actas Dermo-Sifiliograficas

Volumn 104, Issue 3, 2013, Pages 181-203

  Fuertes, L ^a   Santonja, C ^a   Kutzner, H ^b   Requena, L ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Dermatopathologische Gemeinschaftslabor   (Germany)

Author keywords

Dermatopathology; Endothelial markers; Immunohistochemistry; Lymphatic and hematologic markers; Markers in skin infections; Melanocytic markers; Muscle markers; Neural markers; Neuroendocrine markers; Skin metastases

Indexed keywords

ANTIBODY; PEROXIDASE;

IMMUNOHISTOCHEMISTRY; MELANOMA; REVIEW; SKIN DISEASE; SKIN INFECTION; SKIN METASTASIS;

EID: 84876565516     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.ad.2012.02.018     Document Type: Short Survey

References (86)

1. Wasserman J, Maddox J, Racz M, Petronic-Rosic V. Update on immunohistochemical methods relevant to dermatopathology. Arch Pathol Lab Med. 2009;133: 1053-61.
2. Walsh N, Boutilier R, Glasgow D, Schaffelburg M. Exclusive involvement of folliculosebaceous units by herpes. A reflection of early herpes zoster. Am J Dermatopathol. 2005;27: 189-94.
3. Aragües M, Sánchez Pérez J, Fraga J, Burgos E, Noguerado A, García Díez A. Hairy leucoplakia-a clinical, histopathological and ultrastructural study in 33 patients. Clin Exp Dermatol. 1990;15: 335-9.
4. Fraga Fernández J, Chavez Benito MA, Burgos Lizaldez E, Aragües Montanes M. Oral hairy leukoplakia. A histopathologic study of 32 cases. Am J Dermatopathol. 1990;12: 571-8.
5. Robin YM, Guillou L, Michels JJ, Coindre JM. Human herpesvirus 8 immunostaining. A sensitive and specific method for diagnosing Kaposi sarcoma in paraffin-embedded sections. Am J Clin Pathol. 2004;121: 330-4.
6. Cheuk W, Wong KO, Wong CS, Dinkel JE, Ben-Dor D, Chan JK. Immunostaining for human herpesvirus 8 latent nuclear antigen- 1 helps distinguish Kaposi sarcoma from its mimickers. Am J Clin Pathol. 2004;121: 335-42.
7. Jung HS, Choi YL, Choi JS, Roh JH, Pyon JK, Woo KJ, et al. Detection of Merkel cell polyomavirus in Merkel cell carcinomas and small cell carcinomas by PCR and immunohistochemistry. Histol Histopathol. 2011;26: 1231-41.
8. Schwarz TF, Wiersbitzky S, Pambor M. Case report: detection of parvovirus B19 in a skin biopsy of a patient with erythema infectiosum. J Med Virol. 1994;43: 171-4.
9. Takahashi M, Ito M, Sakamoto F, Shimizu N, Furakawa T, Takahashi M, et al. Human parvovirus B19 infection: immunohistochemical and electron microscopic studies of skin lesions. J Cutan Pathol. 1995;22: 168-72.
10. Santonja C, Nieto-González G, Santos-Briz A, De las Nieves Gutiérrez Zufiaurre M, Cerroni L, Kutzner H, et al. Immunohistochemical detection of parvovirus B19 in "gloves and socks" papular purpuric syndrome: direct evidence for viral endothelial involvement. Report of three cases and review of the literature. Am J Dermatopathol. 2011;33: 790-5.
11. Martín Ezquerra G, Fernández Casado A, Barco D, Jucglá A, Juanpere-Rodero N, Manresa JM, et al. Treponema pallidum distribution pattern in mucocutaneous lesions of primary and secondary syphilis: an immunohistochemical and ultrastructural study. Hum Pathol. 2009;40: 624-30.
12. Kutzner H, Argenyi ZB, Requena L, Rütten A, Hügel H. A new application of BCG antibody for rapid screening of various tissue microorganisms. J Am Acad Dermatol. 1998;38: 56-60.
13. Khosravi Shahi P, Gil Herrera J, Del Castillo Rueda A. La importancia clínica de los polimorfismos del gen CD45. An Med Interna (Madrid). 2005;22: 459-60.
14. Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113: 4885-93.
15. Hoang MP, Mahalingam M, Selim MA. Immunohistochemistry in the diagnosis of cutaneous neoplasms. Future Oncol. 2010;6: 93-109.
16. Hoefnagel JJ, Vemeer MH, Jansen PM, Fleuren GJ, Meijer CJ, Willemze R. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol. 2003;149: 1183-91.
17. Cerroni L, Volkenandt M, Rieger E, Soyer HP, Kerl H. Bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas. J Invest Dermatol. 1994;102: 231-5.
18. Kanner WA, Brill LB, Patterson JW, Wick MR. CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma. J Cutan Pathol. 2010;37: 744-50.
19. Kelemen K, Peterson LC, Helenowski I, Goolsby CL, Jovanovic B, Miyata S, et al. CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- disease. Am J Clin Pathol. 2008;130: 166-77.
20. Murphy M, Fullen D, Carlson JA. Low CD7 expression in benign and malignant cutaneous lymphocytic infiltrates: experience with an antibody reactive with paraffin-embedded tissue. Am J Dermatopathol. 2002;24: 6-16.
21. Werner B, Massone C, Kerl H, Cerroni L. Large CD30-positive cells in benign, atypical lymphoid infiltrates of the skin. J Cutan Pathol. 2008;35: 1100-7.
22. De Diego J, Berridi D, Saracibar N, Requena L. Cutaneous pseudolymphoma in association with molluscum contagiosum. Am J Dermatopathol. 1998;20: 518-21.
23. Nathan DL, Belsito DV. Carbamazepine-induced pseudolymphoma with CD30-positive cells. J Am Acad Dermatol. 1998;38: 806-9.
24. Rose C, Starostik P, Broker EB. Infection with parapoxvirus induced CD-30 positive cutaneous infiltrates in humans. J Cutan Pathol. 1999;26: 520-2.
25. Kim KJ, Lee MW, Choi JH, Sung KJ, Moon KC, Koh JK. CD30-positive T-cell rich pseudolymphoma induced by gold acupuncture. Br J Dermatol. 2002;146: 882-4.
26. Gallardo F, Barranco C, Toll A, Pujol RM. CD30 antigen expression in cutaneous inflammatory infiltrates of scabies: a dynamic immunophenotypic pattern that should be distinguished from lymphomatoid papulosis. J Cutan Pathol. 2002;29: 368-73.
27. Moreno Ramírez D, García Escudero A, Ríos Martín JJ, Herrera Saval A, Camacho F. Cutaneous psudolymphoma in association with molluscum contagiosum in an elderly patient. J Cutan Pathol. 2003;30: 473-5.
28. Yue LZ, Fu R, Wang HQ, Li LJ, Hu HR, Fu L, et al. Expression of CD123 and CD114 on the bone marrow cells of patients with myelodysplastic syndrome. Chin Med J. 2010;123: 2034-7.
29. Du X, Ho M, Pastan I. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. J Immunother. 2007;30: 607-13.
30. Del Giudice I, Matutes E, Morilla R, Morilla A, Owusu-Ankomah K, Rafiq F, et al. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica. 2004;89: 303-8.
31. Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm. Morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol. 2010;34: 75-87.
32. Requena L, Kutzner H, Palmedo G, Pascual M, Fernández- Herrera J, Fraga J, et al. Histiocytoid Sweet syndrome: a dermal infiltration of immature neutrophilic granulocytes. Arch Dermatol. 2005;141: 834-42.
33. Pulford KAF, Sipos A, Cordell JL, Stross WP, Mason DY. Distribution of the CD68 macrophage/myeloid associated antigen. Immunology. 1990;2: 973-80.
34. Lau SK, Chu PG, Weiss LM. CD163: a specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol. 2004;122: 794-801.
35. Chu P, Chang K, Arber D, Weiss L. Inmunophenotyping of hematopoietic neoplasms. Sem Diag Pathol. 2000;17: 236-56.
36. Soslow RA, Bhargava V, Warnke RA. MIC2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities. Hum Pathol. 1997;28: 1158-65.
37. Traweek ST, Arber DA, Rappaport H, Brynes RK. Extramedullary myeloid cell tumors. An immunohistochemical and morphologic study of 28 cases. Am J Surg Pathol. 1993;17: 1011-9.
38. de Jonge HJ, Woolthuis CM, Vos AZ, Mulder A, van den Berg E, Kluin PM, et al. Gene expression profiling in the leukemic stem cell-enriched CD34(+) fraction identifies target genes that predict prognosis in normal karyotype AML. Leukemia. 2011;25: 1825-33.
39. Bernstein ID, Andrews RG, Cohen SF, McMaster BE. Normal and malignant human myelocytic and monocytic cells identified by monoclonal antibodies. J Immunol. 1982;128: 876-81.
40. Natkunam Y, Rouse RV. Utility of paraffin section immunohistochemistry for C-KIT (CD117) in the differential diagnosis of systemic mast cell disease involving the bone marrow. Am J Surg Pathol. 2000;24: 81-91.
41. Lau SK, Chu PG, Weiss LM. Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders. Am J Surg Pathol. 2008;32: 615-9.
42. Garrido-Ruiz MC, Requena L, Ortiz P, Pérez-Gómez B, Alonso SR, Rodríguez Peralto JL. The immunohistochemical profile of Spitz nevi and conventional (non-Spitzoid) melanomas: a baseline study. Mod Pathol. 2010;23: 1215-24.
43. Minami S, Lum CA, Kitagawa KM, Namiki TS. Immunohistochemical expression of cyclooxygenage-2 in melanocytic skin lesions. Int J Dermatol. 2011;50: 24-9.
44. Sundram U, Harvell JD, Rouse RV, Natkunam Y. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA. Mod Pathol. 2003;16: 802-10.
45. Prieto VG, Shea CR. Use of immunohistochemistry in melanocytic lesions. J Cutan Pathol. 2008;35 Suppl 2:S1-10.
46. Kamino H, Tam S, Tapia B, Toussaint S. The use of elastin immunostain improves the evaluation of melanomas associated with nevi. J Cutan Pathol. 2009;36: 845-52.
47. Pages C, Rochaix P, al Saati T, Valmaray-Degano S, Boulinguez S, Launay F, et al. KBA.62: a useful marker for primary and metastatic melanomas. Hum Pathol. 2008;39: 1136-42.
48. El Shabrawi-Caelen L, Kerl H, Cerroni L. Melan A: not a helpful marker in distinction between melanoma in situ in sun-damaged skin and pigmented actinic keratosis. Am J Dermatopathol. 2004;26: 364-6.
49. Monteagudo C, Calduch L, Navarro S, Joan-Figueroa A, Llombart-Bosch A. CD99 immunoreactivity in atypical fibroxanthoma: a common feature of diagnostic value. Am J Clin Pathol. 2002;117: 126-31.
50. McNiff JM, Subtil A, Cowper SE, Lazova R, Glusac EJ. Cellular digital fibromas. Distinctive CD34-positive lesions that may mimic dermatofibrosarcoma protuberans. J Cutan Pathol. 2005;32: 413-8.
51. Ostler DA, Prieto VG, Reed JA, Deavers MT, Lazar AJ, Ivan D. Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: an immunohistochemical study of 117 cases. Mod Pathol. 2010;23: 567-73.
52. Orta L, Klimstra DS, Qin J, Mecca P, Tang LH, Busam KJ, et al. Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient's age or other clinical characteristics. Am J Surg Pathol. 2009;33: 934-44.
53. Chhibber V, Dresser K, Mahalingam M. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir- Torre syndrome. Mod Pathol. 2008;21: 159-64.
54. Popnikolov NK, Gatalica Z, Colombe-Grimmer MI, Sánchez RL. Loss of mismatch repair proteins in sebaceous gland tumors. J Cutan Pathol. 2003;30: 178-84.
55. Pham TT, Selim MA, Burchette Jr JL, Madden J, Turner J, Herman C. CD10 expression in trichoepithelioma and basal cell carcinoma. J Cutan Pathol. 2006;33: 123-8.
56. Sanders DSA, Carr RA. The use of immunohistochemistry in the differential diagnosis of common epithelial tumors of the skin. Curr Diagn Pathol. 2007;13: 237-51.
57. Tellechea O, Reis JP, Domínguez JC, Baptista AP. Monoclonal antibody Ber Ep4 distinguishes basal cell carcinoma from squamous-cell carcinoma of the skin. Am J Dermatopathol. 1993;15: 452-5.
58. Swanson PE, Fitzpatrick MM, Ritter JH, Glusac EJ, Wick MR. Immunohistologic differential diagnosis of basal cell carcinoma, squamous cell carcinoma, and trichoepithelioma in small cutaneous biopsy specimens. J Cutan Pathol. 1998;25: 153-9.
59. Beer TW, Sheperd P, Theaker JM. BerEP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinomas of the skin. Histopathology. 2000;37: 218-23.
60. Requena L, Prieto VG, Requena C, Sarasa JL, Manzano R, Seco M, et al. Primary signet-ring cell/histiocytoid carcinoma of the eyelid: a clinicopathologic study of 5 cases and review of the literature. Am J Surg Pathol. 2011;35: 378-91.
61. Ivan D, Nash J, Prieto V, Calonje E, Lyle S, Diwan AH, et al. Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from adenocarcinoma to the skin. J Cutan Pathol. 2007;34: 474-80.
62. Qureshi HS, Ormsby AH, Lee MW, Zarbo RJ, Ma CK. The diagnostic utility of p63, CK5/6, CK7, and CK20 in distinguishing primary cutaneous adnexal neoplasms from metastatic carcinomas. J Cutan Pathol. 2004;31: 145-52.
63. Tsubura A, Senzaki H, Sasaki M, Hilgers J, Morii S. Immunohistochemical demonstration of breast-derived and/or carcinoma-associated glycoproteins in normal skin appendages and their tumors. J Cutan Pathol. 1992;19: 73-9.
64. Alcaraz I, Cerroni L, Rütten A, Kutzner H, Requena L. Cutaneous metastases from internal malignancies: a clinicopathologic and immunohistochemical review. Am J Dermatopathol. 2012;34: 347-93.
65. Fujiwara M, Taube J, Sharma M, McCalmont TH, Kim J. PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases. J Cutan Pathol. 2010;37: 938-43.
66. Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010;34: 1147-54.
67. Ramachandra S, Gillett CE, Millis RR. A comparative immunohistochemical study of mammary and extramammary Paget's disease and superficial spreading melanoma, with particular emphasis on melanocytic markers. Virchows Arch. 1996;429: 371-6.
68. Folpe AL, Billings SD, McKenney JK, Walsh SV, Nusrat A, Weiss SW. Expression of claudin-1, a recently described tight junction-associated protein, distinguishes soft tissue perineurioma from potential mimics. Am J Surg Pathol. 2002;26: 1620-6.
69. Karanjawala ZE, Illei PB, Ashfaq R, Infante JR, Murphy K, Pandey A, et al. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol. 2008;32: 188-96.
70. Ohene-Abuakwa Y, Noda M, Perenyi M, Kobayashi N, Kashima K, Hattori T, et al. Expression of the E-cadherin/catenin (a-, b-, g-) complex correlates with the macroscopic appearance of early gastric cancer. J Pathol. 2000;192: 433-9.
71. Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, Giannopoulou I, Keramopoulos A, Davaris P, et al. Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopathology. 2002;40: 536-46.
72. Molina-Ortiz I, Bartolomé RA, Hernández-Varas P, Colo GP, Teixidó J. Overexpression of E-cadherin on melanoma cells inhibits chemokine-promoted invasion involving p190RhoGAP/p120ctn-dependent inactivation of RhoA. J Biol Chem. 2009;284: 15147-57.
73. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol. 2002;55: 662-8.
74. Nascimento AF, Fletcher CD. The controversial nosology of benign nerve sheath tumors: neurofilament protein staining demonstrates intratumoral axons in many sporadic schwannomas. Am J Surg Pathol. 2007;31: 1363-70.
75. Feany MB, Anthony DC, Fletcher CDM. Nerve sheath tumors with hybrid features of neurofibroma and schwannoma: a conceptual challenge. Histopathology. 1998;32: 405-10.
76. Zamecnik M. Hybrid neurofibroma/schwannoma versus schwannoma with Antoni B areas. Histopathology. 2000;36: 473.
77. Kazakov DV, Pitha J, Sima R, Vanecek T, Shelekhova K, Mukensnabl P, et al. Hybrid peripheral nerve sheath tumors: schwannoma-perineuroma and neurofibroma-perineuroma. A report of three cases in extradigital locations. Ann Diagn Pathol. 2005;9: 16-23.
78. Laskin WB, Fetsch JF, Miettinen M. The "neurothekeoma": immunohistochemical analysis distinguishes the true nerve sheath myxoma from its mimics. Hum Pathol. 2000;31: 1230-41.
79. Fetsch JF, Laskin WB, Miettinen M. Nerve sheath myxoma. A clinicopathologic and immunohistochemical analysis of 57 morphologically distinctive, S-100 protein- and GFAP-positive myxoid peripheral nerve sheath tumors with a predilection for the extremities and a high local recurrence rate. Am J Surg Pathol. 2005;29: 1615-24.
80. Fetsch JF, Laskin WB, Hallman JR, Lupton GP, Miettinen M. Neurothekeoma: an analysis of 178 tumors with detailed immunohistochemical data and long-term patient follow-up information. Am J Surg Pathol. 2007;31: 1103-14.
81. Argenyi ZB, LeBoit PE, Santa Cruz DJ, Swanson PE, Kutzner H. Nerve sheath myxoma (neurothekeoma) of the skin: Light microscopic and immunohistochemical reappraisal of the cellular variant. J Cutan Pathol. 1993;20: 294-303.
82. Husain S, Silvers DN, Halperin AJ, McNutt NS. Histologic spectrum of neurothekeoma and the value of immunoperoxidase staining for S-100 protein in distinguishing it from melanoma. Am J Dermatopathol. 1994;16: 496-503.
83. Wang AR, May D, Bourne P, Scott G. PGP 9.5. A marker for cellular neurothekeoma. Am J Surg Pathol. 1999;23: 1401-7.
84. Page RN, King R, Mihm Jr MC, Googe PB. Microphthalmia transcription factor and NKI/C3 expression in cellular neurothekeoma. Mod Pathol. 2004;17: 230-4.
85. Fullen DR, Lowe L, Su LD. Antibody to S100a6 protein is a sensitive immunohistochemical marker for neurothekeoma. J Cutan Pathol. 2003;30: 118-22.
86. Ralston J, Chiriboga L, Nonaka D. MASH1: a useful marker in differentiating pulmonary small cell carcinoma from Merkel cell carcinoma. Mod Pathol. 2008;21: 1357-62.